« Back
Home /
Leniolisib

Leniolisib

Item no.	HY-17635-1mg
Manufacturer	MedChem Express
CASRN	1354690-24-6
Amount	1 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 50 mg 5 mg
Category	Neuroscience Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.19
Formula	C21H25F3N6O2
Citations	[1]Rao V, et al. Effective 'Activated PI3Kd Syndrome' -targeted therapy with PI3Kd inhibitor leniolisib. The New England journal of medicine: NEJM. ISSN 0028-4793; 1533-4406<br/>[2]Hoegenauer K, et al. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980.
Smiles	CCC(N1C[C@@H](NC2=C(CN(C3=CC(C(F)(F)F)=C(OC)N=C3)CC4)C4=NC=N2)CC1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CDZ173
Available
Product Description	Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	450.46
Clinical Information	Launched
Manufacturers Research Area	Inflammation/Immunology
Solubility	DMSO : 100 mg/mL (ultrasonic)
Target	PI3K
Manufacturers Target	PI3K
Isoform	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ
Manufacturers Pathway	PI3K/Akt/mTOR
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17635-1mg-safety-datasheet.pdf